← brief for 2026-09-09 · Slowing decline

Keeping RAASi Treatment With Optimal Potassium Control

Key takeaways

Drugs called RAAS inhibitors protect the kidneys, but they can push potassium in the blood too high, so doctors often cut the dose or stop them. This trial tests a different fix: keep the kidney-protective drug and add sodium zirconium cyclosilicate (Lokelma), a medicine that pulls extra potassium out of the body. It compares that against the usual approach of reducing or stopping the RAAS inhibitor. The study is open-label, meaning everyone knows which treatment they got. There are no results yet.

Who did this work

Run by Fundación para la Investigación del Hospital Clínico de Valencia.
Sites: Hospital General Universitario Dr. Balmis · Hospital Universitario Vall d'Hebrón · Hospital Universitario 12 de Octubre · Hospital Clínico Universitario de Valencia · Hospital Universitario Doctor Peset

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-09-09
https://clinicaltrials.gov/study/NCT06578533